H. W. Reesink

1.6k citations

23 papers · 1.0k indexed · 1 hit paper · h-index 13

Epidemiology top 5%
Hepatology top 1%
Infectious Diseases top 10%
Hematology top 10%
Virology top 5%

Co-authors: E.E. Reerink‐Brongers C.L. van der Poel H.T.M. Cuypers C. Y. Yeung P.N. Lelie Jan Desmyter Hans L. Zaaijer H. T. M. Cuypers
Topics: Hepatitis B Virus Studies (12 papers)Hepatitis C virus research (9 papers)Blood groups and transfusion (7 papers)
Cited by: Hepatology Virology Epidemiology
Journals: The Lancet Transfusion Vox Sanguinis
Partner nations: Netherlands United States Belgium

In The Last Decade

H. W. Reesink

22 papers receiving 915 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PREVENTION OF THE HBsAg CARRIER STATE IN NEWBORN INFANTS OF MOTHERS WHO ARE CHRONIC CARRIERS OF HBsAg AND HBeAg BY ADMINISTRATION OF HEPATITIS-B VACCINE AND HEPATITIS-B IMMUNOGLOBULIN

1984 340 citations H. W. Reesink, E.E. Reerink‐Brongers et al. The Lancet profile →

Peers

Countries citing papers authored by H. W. Reesink

Since Specialization

Citations

This map shows the geographic impact of H. W. Reesink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. W. Reesink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. W. Reesink more than expected).

Fields of papers citing papers by H. W. Reesink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. W. Reesink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. W. Reesink. The network helps show where H. W. Reesink may publish in the future.

Co-authorship network of co-authors of H. W. Reesink

This figure shows the co-authorship network connecting the top 25 collaborators of H. W. Reesink. A scholar is included among the top collaborators of H. W. Reesink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. W. Reesink. H. W. Reesink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	[The predictive value of autoantibodies in disseminating lupus erythematosus and rheumatoid arthritis]. 2005 ·PubMed ·B.A.C. Dijkmans,D. van Schaardenburg,Irene E. van der Horst‐Bruinsma,H. W. Reesink,Jan P. Vandenbroucke,Maarten Boers	1
2	West Nile virus and blood donors (letter) 2003 ·The Lancet ·J.‐J. Lefrère,Jean Pierre Allain,Daniele Prati,Sílvia Sauleda,H. W. Reesink	2
3	[Coinfection with hepatitis C virus and HIV]. 2003 ·PubMed ·(unknown),H. W. Reesink,J Lange	3
4	Blood Transfusion in Premature or Young Infants with Polyagglutination and Activation of the T Antigen 1999 ·Vox Sanguinis ·C. P. Engelfriet,H. W. Reesink	15
5	Reliability of the third‐generation recombinant immunoblot assay for hepatitis C virus 1995 ·Transfusion ·M. Damen,Hans L. Zaaijer,H. T. M. Cuypers,Hans Vrielink,C.L. van der Poel,H. W. Reesink,P.N. Lelie	61
6	Transmission of Hepatitis C Virusby Anti-HCV-Negative Blood Transfusion 1995 ·Vox Sanguinis ·Hans Vrielink,C.L. van der Poel,H. W. Reesink,Hans L. Zaaijer,P.N. Lelie	18
7	What Is the Best Technique for the Detection of Red Cell Alloantibodies? 1995 ·Vox Sanguinis ·C. P. Engelfriet,H. W. Reesink,(unknown),F Carbonell,R. Mitchell,(unknown),(unknown),Michel Goldman,Francine Décary,(unknown),H. Gerber,(unknown),L. Kornstad,J. J. Moulds,M.A.M. Overbeeke,Anna Pirkola,D. Voak,Willem H. Ouwehand	8
8	Hepatitis C virus six years on 1994 ·The Lancet ·C.L. van der Poel,H. W. Reesink,H.T.M. Cuypers	165
9	Recombinant immunoblot assay reaction patterns and hepatitis C virus RNA in blood donors and non‐A, non‐B hepatitis patients 1993 ·Transfusion ·Dorine Bresters,Hans L. Zaaijer,H. T. M. Cuypers,H. W. Reesink,I.N. Winkel,P.J. van Exel‐Oehlers,(unknown),P. L. M. Jansen,C.L. van der Poel,P.N. Lelie	45
10	Prenatal Management of Fetal Alloimmune Thrombocytopenia: Editorial 1993 ·Vox Sanguinis ·H. W. Reesink,C. P. Engelfriet,Francine Décary,Mindy Goldman,Cécile Kaplan,(unknown),C. H. Rodeck,A. H. Waters,C. Mueller‐Eckhardt,G. Giers,R. Bald,E. F. van Leeuwen,Humphrey H.H. Kanhai,Anneke Brand,James B. Bussel	13
11	Diagnosis and Prevalence of HIV‐2 Antibodies in Different Population Subsets in The Netherlands 1989 ·Vox Sanguinis ·C.L. van der Poel,P.N. Lelie,H. W. Reesink,(unknown),(unknown),(unknown),(unknown),Johannes Buitenwerf,Andrew Cameron,J Huisman	2
12	Blood Donors with Indeterminate Anti‐p24^gagReactivity in HIV‐1 Western Blot: Absence of Infectivity to Transfused Patients and in Virus Culture 1989 ·Vox Sanguinis ·C.L. van der Poel,P.N. Lelie,H. W. Reesink,P.J. van Exel‐Oehlers,M Tersmette,(unknown),(unknown),J Huisman	24
13	Transmission of HIV by Transfusion of ELISA‐Negative Blood 1988 ·Vox Sanguinis ·C.L. van der Poel,H. W. Reesink,Marinus H. J. van Oers,Freerk W. van der Meulen	6
14	EVALUATION OF SIX ENZYME IMMUNOASSAYS FOR ANTIBODY AGAINST HUMAN IMMUNODEFICIENCY VIRUS 1986 ·The Lancet ·H. W. Reesink,J Huisman,(unknown),I.N. Winkel,A. C. Hekker,P.N. Lelie,W. P. Schaasberg,C. Aaij,(unknown),Jan Desmyter,Jaap Goudsmit	81
15	PREVENTION OF THE HBsAg CARRIER STATE IN NEWBORN INFANTS OF MOTHERS WHO ARE CHRONIC CARRIERS OF HBsAg AND HBeAg BY ADMINISTRATION OF HEPATITIS-B VACCINE AND HEPATITIS-B IMMUNOGLOBULINbreakdown → 1984 ·The Lancet ·(unknown),H. W. Reesink,(unknown),(unknown),E.E. Reerink‐Brongers,C. Y. Yeung,(unknown)	340
16	Efficacy trial of heat-inactivated hepatitis B vaccine (CLB) in male homosexuals in the Netherlands. 1983 ·PubMed ·R A Coutinho,P.N. Lelie,(unknown),(unknown),J Huisman,(unknown),Lawrence J. Schut,E.E. Reerink‐Brongers,H. W. Reesink,W.G. van Aken	3
17	Immunogenicity and safety of heat-inactivated hepatitis B vaccine (CLB) in low risk human volunteers and in patients treated with chronic haemodialysis in the Netherlands. 1983 ·PubMed ·E.E. Reerink‐Brongers,P.N. Lelie,H. W. Reesink,(unknown),H. G. J. Brummelhuis,W.G. van Aken	1
18	Comparison of Six ‘Third‐Generation’ Tests for the Detection of HBsAg 1980 ·Vox Sanguinis ·H. W. Reesink,(unknown),C. Aaij,E.E. Reerink‐Brongers	4
19	Prevention of chronic HBsAg carrier state in infants of HBsAg-positive mothers by hepatitis B immunoglobulin. 1979 ·PubMed ·H. W. Reesink,E.E. Reerink‐Brongers,(unknown),(unknown),(unknown)	44
20	Evaluation of a Simple Method for Determination of IgG Titre Anti‐A or ‐B in Cases of Possible ABO Blood Group Incompatibility 1972 ·Vox Sanguinis ·H. W. Reesink,Mia van der Hart,J. J. van Loghem	24

About H. W. Reesink

H. W. Reesink is a scholar working on Hepatology, Virology and Hematology, having authored 23 papers that have together received 1.0k indexed citations. Recurring topics across this work include Hepatitis B Virus Studies (12 papers), Hepatitis C virus research (9 papers) and Blood groups and transfusion (7 papers). The work is most often cited by research in Hepatology (649 citations), Virology (106 citations) and Epidemiology (742 citations). H. W. Reesink has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include E.E. Reerink‐Brongers, C.L. van der Poel, H.T.M. Cuypers, C. Y. Yeung, P.N. Lelie, Jan Desmyter, Hans L. Zaaijer, H. T. M. Cuypers, I.N. Winkel and Hans Vrielink. Their work appears in journals such as The Lancet, Transfusion and Vox Sanguinis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact